Who Owns Candel Therapeutics Stock?
NASDAQ: CADLHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
Market open · Delayed 15 min · as of Oct 9, 10:43 AM ET
Ownership breakdown
- Held by institutions
- 67.65%
- Held by insiders
- 14.65%
- Institutional holders
- 186
- Institutions 67.7%
- Insiders 14.7%
- Public and other 17.7%
Who owns Candel Therapeutics stock?
Institutional investors own about 67.7% of Candel Therapeutics's shares, spread across 186 institutions that file 13F reports. That level of institutional ownership is moderate. Insiders, including executives, directors and large founding shareholders, hold 14.65% of CADL.
The largest institutional holders are FMR, LLC (14.36%), RTW Investments LP (8.39%) and Blackrock Inc. (6.49%). Together, the top 10 institutions control 54.3% of shares outstanding. In their latest filings, 8 of the top 10 institutions increased their CADL positions and 0 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of CADL
| Institution | Shares | % Held | Change |
|---|---|---|---|
| FMR, LLC | 10.99M | 14.36% | +0.0% |
| RTW Investments LP | 6.42M | 8.39% | 0.0% |
| Blackrock Inc. | 4.97M | 6.49% | +59.8% |
| State Street Corporation | 3.55M | 4.64% | +333.7% |
| Acorn Capital Advisors, LLC | 3.50M | 4.57% | 0.0% |
| Portolan Capital Management, LLC | 3.49M | 4.56% | +20.6% |
| Saturn V Capital Management LP | 3.30M | 4.32% | +14.1% |
| Vanguard Capital Management LLC | 2.69M | 3.52% | +9.4% |
| Geode Capital Management, LLC | 1.57M | 2.05% | +51.7% |
| Millennium Management Llc | 1.09M | 1.43% | +3.2% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of CADL
| Fund | Shares | % Held |
|---|---|---|
| Fidelity Select Portfolios-Select Biotechnology Portfolio | 4.86M | 6.36% |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 2.29M | 2.99% |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.14M | 2.79% |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.97M | 2.57% |
| Fidelity Rutland Square TRT II-Strategic Advisers U.S. Total Stock Fd. | 1.91M | 2.50% |
| iShares Trust-iShares Russell 2000 ETF | 1.63M | 2.12% |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 693.03K | 0.91% |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company K6 Fund | 659.19K | 0.86% |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 659.08K | 0.86% |
| Fidelity Mt. Vernon Street Trust-Fidelity Series Growth Company Fund | 602.77K | 0.79% |
Frequently asked questions
Who is the largest shareholder of Candel Therapeutics?
FMR, LLC is the largest institutional shareholder of CADL, owning 14.36% of shares outstanding (10.99M shares) as of its latest 13F filing.
What percentage of Candel Therapeutics is owned by institutions?
Institutions own about 67.7% of CADL shares and 79.3% of the public float.
How much of Candel Therapeutics do insiders own?
Insiders, such as officers and directors, own about 14.65% of CADL shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.